Vaccines Europe

📢 The 2024 pipeline review of Vaccines Europe member companies is published today, highlighting the transformative power of immunisation in addressing evolving health challenges such as the ageing population, #AMR, and climate change. With 98 vaccine candidates in our members’ pipeline across 12 different technology platforms, vaccine innovation plays a key role in public health and the resilience of societies and economies https://bit.ly/3ZdJO1U #WeWontRest 

Our first quarterly newsletter for 2025 is here. From the value of investing in prevention, to the role of immunisation in addressing #AMR and our upcoming webinar on vaccines and the EU #HTA Regulation, learn more about our recent activities ➡️ https://bit.ly/4cc2eGn

Great visual from One Health Trust reminding us that global challenges can't be tackled in siloes. 🛠️ We need to use all tools in our toolbox to address antimicrobial resistance: from prevention to diagnostic and cure. 🎯 By targeting the root causes of #AMR, #vaccines, in combination with other infection prevention & control measures can alleviate some of the pressure on antimicrobials and preserve their value. 💡 We need to increase the uptake of existing vaccines, recognise their full value, and improve our surveillance systems to foster the right conditions for continued innovation.

Non-communicable diseases are placing an increasing strain on EU health systems, driving up costs and shortening life expectancy. A new report highlights that investing in #prevention and #treatment saves lives and yields significant economic benefits. https://lnkd.in/dctBmRAn

During the #COVID19 pandemic, several strategies helped shorten time to population access to vaccines. Employing these strategies now would help improve the resilience of vaccine supply chains:  ✅ Policies that support manufacturing capacities, free trade of raw materials and vaccines, and the freedom to select suppliers  ✅ Harmonising global regulatory standards  ✅ Timely sharing of epidemiological data and information  https://bit.ly/47viT5i #WeWontRest 

Vaccine manufacturing is a long and complex process. For example, the #flu seasonal vaccine takes between 6-12 months to produce, while the most complex vaccines, such as those for #pneumococcal infections, can take more than 36 months https://bit.ly/47viT5i #WeWontRest  Anna Czwarno

By understanding community needs early on, vaccine manufacturers can more accurately predict how many vaccines the population requires and optimise production to meet those needs. To ensure this process works well, early and continuous dialogue between manufacturers and health authorities at European, national and regional level is paramount https://bit.ly/47viT5i #WeWontRest 

Join our team! We're looking for a Public Affairs Intern to contribute to our advocacy activities in Brussels. If you're interested, please apply by 11th April. Find out how here ➡️ https://bit.ly/4kWIsCA

We were excited to participate in the FOKUS Patient Future Days conference in Stockholm today, where Charlotte Vernhes explained why vaccines are a vital, yet underused tool in the fight against #AMR. Vaccines address the root causes of AMR and in order to maximise their potential to curb the spread of antimicrobial-resistant infections, urgent action in needed: ✅ Improving the coverage rates for existing vaccines through a life-long approach ✅ Recognising the full value of vaccines as essential tools against AMR ✅ Enhancing surveillance systems to address data gaps and showcase AMR vaccine value. #fokuspatient #futuredays

Manufacturing and packaging complexities, challenges in understanding demand and a number of external factors can cause delays in vaccine supply. We need to strengthen the supply chain to ensure people get the vaccines they need https://bit.ly/47viT5i #WeWontRest  Kajsa Hagspiel